Eribulin Mesylate Significantly Improved Overall Survival In Patients With Locally Re
 

Global EMBRACE Study Compared Eribulin to Treatment of Physician's Choice. Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients...

More...